New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
05:39 EDTMBIIMarrone Bio downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Marrone Bio to Neutral with an $11 price target citing sales uncertainty and the COO departure following the company's Q2 results.
News For MBII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2015
08:42 EDTMBIIMarrone Bio receives letter of continued noncompliance from Nasdaq
Marrone Bio announced that, as anticipated, it has received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market notifying the company of its continued noncompliance with NASDAQ Listing Rule 5250(c)(1) as a result of the company's failure to timely file its Quarterly Report on Form 10-Q for the three months ended June 30 on August 15. As reported in the company's Notification of Late Filing on Form 12b-25 filed with the SEC on August 17, the Form 10-Q will not be filed with the SEC until after the completion of company management's evaluation of the necessity, nature and scope of any restatements to its previously filed financial statements. The company currently expects that it will be able to file all delinquent reports, including the Form 10-Q, prior the November 9 expiration of the stay on suspension of trading granted by NASDAQ for the company to regain compliance with NASDAQ's filing requirement.
08:40 EDTMBIIMarrone Bio COO James Iademarco to resign
Marrone Bio Innovations announced that James Iademarco, the company's president and COO since January, has elected to resign effective August 31. To assist with the transition of various pending matters, Iademarco has agreed to remain available to advise the company in a consulting capacity for an additional period of up to 90 days.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use